Medicine

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.

S. Diem, S. Schmid, M. Krapf, L. Flatz, D. Born, W. Jochum, A. Templeton, M. Früh

2017.9.1LUNG CANCER

DOI: 10.1016/j.lungcan.2017.07.024

tlooto Summary

Elevated pre-treatment NLR and PLR are associated with shorter OS and PFS and with lower response rates in patients with metastatic NSCLC treated with nivolumab independently of other prognostic factors.

Abstract

Abstract is not available.

Citation format

DIEM, S., et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. LUNG CANCER, 2017, 111: 176–181.